AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$HALO

Torley Helen sold $1.1M of HALO

Torley Helen (PRESIDENT AND CEO) sold 16,600 shares of HALOZYME THERAPEUTICS, INC. (HALO) at $66.31 ($1.10M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Torley Helen
Published Jun 4, 2026, 12:06 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HALO
Neutral
medium confidence
Mentioned
$HALO
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HALONeutralLow
01

Why it matters

The market may briefly reassess sentiment around management’s outlook, but the pre-arranged nature usually limits inference about new negative fundamentals.

02

Market read

A disclosed CEO sale at a specific price/value; likely low incremental trading impact absent additional corroborating news.

03

What to watch

The filing doesn’t indicate whether other insiders/funds are selling or buying; without follow-on transactions, the signal may be overstated.

Relevance 7/10Novelty 6/10Timing: SEC Form 4 filed June 3 for a June 2 sale

Background

This is an SEC Form 4 insider transaction disclosure for HALO’s CEO (Torley Helen) showing an open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$HALONeutralMedium confidence
Context

HALO’s CEO sold 16,600 shares in an open-market transaction disclosed via SEC Form 4 on June 2 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be modest and fade unless follow-on selling accelerates.

Evidence & confidence

The filing provides a specific sale price/value and confirms a pre-arranged 10b5-1 plan, reducing the likelihood of immediate negative information content.

Market effects

Sector

Minimal—single-company insider transaction without new clinical/regulatory or deal information.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated or large CEO sales can still pressure sentiment if investors interpret it as reduced confidence.

Key entities

  • issuer
    HALOZYME THERAPEUTICS, INC.

    Subject of the insider transaction disclosure; CEO sold shares via open-market sale under a 10b5-1 plan.

  • insider
    Torley Helen

    President and CEO who sold 16,600 shares at $66.3140 on 2026-06-02.

Read at source← All news

Related articles

AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min
AUG 7
$HALOHighAI 9/10

Halozyme climbs after record Q2 results and higher 2026 outlook

Halozyme Therapeutics (HALO) shares rose about 15% after the company reported record Q2 2026 results and raised 2026 guidance, according to Halozyme’s investor release. Q2 total revenue increased 48% to $481 million, royalty revenue rose 50% to $307.7 million. Full-year 2026 revenue guidance was raised to $1.835B-$1.910B and non-GAAP diluted EPS to $8.65-$9.00.

quiverquant.com4 min
AUG 7
$HALOHighAI 9/10

Why is Halozyme Therapeutics stock surging today?

Halozyme Therapeutics shares rose about 6.1% pre-open after the company reported record Q2 2026 results. Total revenue increased 48% to $481 million and non-GAAP EPS was $2.28, both above expectations. Royalty revenue hit $307.7 million. Halozyme raised full-year 2026 guidance to non-GAAP EPS of $8.65-$9.00 and revenue of $1.835-$1.910 billion, and said it signed five new ENHANZE/Hypercon deals year-to-date.

investing.com2 min
AUG 7
$HALOMedAI 8/10

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported Q2 royalty momentum for VYVGART Hytrulo, with royalty revenue up 143% to $72.6M and total VYVGART brand sales up 60% to $1.5B. Other royalty revenue rose 85% to $54.4M. Halozyme raised 2026 guidance to $1.835B-$1.91B revenue and $8.65-$9.00 non-GAAP EPS, and repurchased $332.8M of stock.

yahoo.com6 min